
Bayer Forms Endometriosis Collaboration with Evotec; Later Expanded to other Indications; BAY1817080 Discontinued
Executive Summary
For the next five years, Bayer HealthCare Pharmaceuticals AG and drug discovery firm Evotec AG have agreed to identify three candidates against multiple targets--selected by both companies--for endometriosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice